Drugs / CODA-001
Trials 9
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT00736593 | Sep 2008 → Jan 2009 | — | OcuNexus Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00654550 | Apr → Sep 2008 | corneal disorder | OcuNexus Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00820703 | Apr → Nov 2009 | ulcer of lower limbs | OcuNexus Therapeutics, Inc. | Terminated | No outcome recorded Stop: Business |
| Phase 26 trials | ||||||
| Phase 2 | NCT05966493 | Aug 2023 → Dec 2025 overdue | corneal disorder | Glaukos Corporation | Recruiting | No outcome recorded |
| Phase 2 | NCT04081103 | Jun 2020 → Feb 2022 | corneal disorder | Glaukos Corporation | Terminated | No outcome recorded |
| Phase 2 | NCT01490879 | Jul 2012 → Feb 2014 | ulcer of lower limbs | OcuNexus Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT01199588 | May 2011 → Dec 2012 | ulcer of lower limbs | OcuNexus Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00820196 | Mar 2009 → Feb 2010 | ulcer of lower limbs | OcuNexus Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00821561 | Mar → Nov 2009 | corneal disorder | OcuNexus Therapeutics, Inc. | Withdrawn | No outcome recorded Stop: Enrollment |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT01165450 Comparator | Nov 2011 → Feb 2014 | corneal disorder | University of California, San Francisco | Terminated | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 11 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CODA-001 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4298053 ↗ |
| Known as | lufepirsen | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04081103 ↗ |
| Known as | Nexagon | “Nexagon® (lufepirsen) is administered topically in the affected eye three (3) times over 28 days.” NCT04081103 ↗9“Nexagon™ in subjects following bilateral PRK for the correction of mild to moderate myopia.” NCT00654550 ↗ |
| Modality | Antisense oligonucleotide | “Lufepirsen is an unmodified connexin43 antisense oligonucleotide.” NCT05966493 ↗ |
| Route | Topical | “when applied to skin wounds created by punch biopsy” NCT00736593 ↗ |